Neuropace, Inc.

As of June 30, 2026, Neuropace, Inc. carries a market capitalization of 544.75M, placing it among publicly traded companies globally. Its enterprise value stands at 562.98M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Neuropace, Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Neuropace, Inc. has 34.28M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 5.40, and the price-to-book ratio stands at 45.84.

These figures are as of June 30, 2026. The EV/Sales ratio of 5.70 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 562.98M versus a market cap of 544.75M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Neuropace, Inc. maintains a current ratio of 4.94, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 588.50, indicating elevated leverage, while an interest coverage ratio of -2.07 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Neuropace, Inc. posted a negative return on equity (ROE) of -122.05, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -18.82, reflecting losses generated across the asset base. The company generates approximately 487,477.19 in revenue per employee across its workforce of 202.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.17 indicates how many times Neuropace, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on November 4, 2026, Neuropace, Inc.'s stock has gained approximately 41.91% over the past 52 weeks. The 50-day moving average sits at 13.60, while the 200-day moving average is 14.92.

Over the twelve months ended June 30, 2026, Neuropace, Inc. generated 98.84M in revenue and converted that into -19.11M in net income, yielding earnings per share of -0.57. EBITDA reached -13.03M, while operating income came in at -15.08M.

As of June 30, 2026, Neuropace, Inc. holds 51.70M in cash and equivalents against 69.93M in total debt, resulting in a net debt position of 46.48M. Total book value stands at 11.88M, with working capital of 68.76M providing operational flexibility.

Neuropace, Inc. produced -11.24M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -369,000.00 in capital expenditures, free cash flow totaled -11.61M - equivalent to -0.35 per share.

Over the twelve months ended June 30, 2026, Neuropace, Inc. posted a gross margin of 79.63, reflecting its pricing power and cost economics. The operating margin of -15.26 and net profit margin of -19.34 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.18: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.26, meaning Neuropace, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Neuropace, Inc. has an Altman Z-Score of -2.96, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.